NeOnc Technologies Holdings Q2 revenue down 20%, strategic partnership secured for $50mln.
ByAinvest
Friday, Aug 22, 2025 5:05 pm ET1min read
NTHI--
• NeOnc Technologies Holdings reports Q2 2025 results • Secured $50 million strategic partnership with Quazar Investment • Partnership will launch clinical trials platform in GCC & MENA • Expanded global footprint • Received non-dilutive NIH funding • CNS cancer therapies in Phase 2 clinical trials • Multi-Phase 2 clinical-stage biotechnology company • Incorporated under Abu Dhabi Global Market (ADGM)
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet